Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Chemours (CC) Other Operating Expenses (2016 - 2025)

Chemours has reported Other Operating Expenses over the past 12 years, most recently at -$132.0 million for Q4 2025.

  • Quarterly results put Other Operating Expenses at -$132.0 million for Q4 2025, down 8.2% from a year ago — trailing twelve months through Dec 2025 was -$142.0 million (down 91.89% YoY), and the annual figure for FY2025 was $24.0 million, up 117.14%.
  • Other Operating Expenses for Q4 2025 was -$132.0 million at Chemours, down from -$34.0 million in the prior quarter.
  • Over the last five years, Other Operating Expenses for CC hit a ceiling of $78.0 million in Q3 2023 and a floor of -$132.0 million in Q4 2025.
  • Median Other Operating Expenses over the past 5 years was $4.5 million (2022), compared with a mean of -$13.7 million.
  • Biggest five-year swings in Other Operating Expenses: surged 120.0% in 2023 and later tumbled 3150.0% in 2024.
  • Chemours' Other Operating Expenses stood at -$10.0 million in 2021, then tumbled by 260.0% to -$36.0 million in 2022, then soared by 111.11% to $4.0 million in 2023, then tumbled by 3150.0% to -$122.0 million in 2024, then decreased by 8.2% to -$132.0 million in 2025.
  • The last three reported values for Other Operating Expenses were -$132.0 million (Q4 2025), -$34.0 million (Q3 2025), and $12.0 million (Q2 2025) per Business Quant data.